Osteoarthritis (OA) of the knee is a prevalent and debilitating condition affecting over 500 million people globally, with a significant burden among individuals aged over 55. Current treatment options are limited to symptom management or invasive procedures such as total knee replacement, which are costly (up to RM 55,000 in private hospitals), carry surgical risks, and are not accessible to all patients. There is an urgent need for a cost-effective, minimally invasive, and biologically based treatment that can promote tissue regeneration and delay or reduce the need for surgery, especially in aging populations.

PEV addressed the issue by offering a minimally invasive, intra-articular injection administered directly into the knee joint, which is derived from the patient’s own blood, PEVs are rich in bioactive proteins, growth factors, cytokines, and immunomodulatory molecules that promote cartilage regeneration and reduce inflammation. PEV is also designed to repair damaged knee cartilage, improve mobility, and delay or avoid costly surgical interventions.

The innovation lies on using the patient's own blood, from which the injection is derived from. It is rich in bioactive protein, & promote growth factors, cartilage regeneration & reduce inflammation. As the treatment is administered via injection, there is minimal to no invasive surgery needed, and is suitable for patients with early-stage osteoarthritis. The solution is also more cost effective compared to total knee replacement